Loss of intraepidermal nerve fibers (IENFs) has been speculated to play a critical role in the development of various neuropathies. In this study, the density of IENFs were studied over time during the induction of Taxol (Bristol-Myers Squibb, NY, USA)-induced chemoneuropathy and compared with the changes in IENFs in animals co-treated with Taxol plus the protective agent minocycline. Rats were injected (intraperitoneally) with 2 mg/kg of Taxol every other day for four injections (day 1, 3, 5, and 7). Minocycline (25 mg/kg) was given in a separate group of rats 24 h prior to the first dose of Taxol and every day for the next 9 days (day 0 through 9). Animals were tested for mechanical paw withdrawal thresholds prior to any drug administrations and again on day 7, 14, and 30. Immunohistochemistry using the panneuronal marker protein gene product 9.5 was performed on glabrous skin of the hind-paw foot pad to stain for IENFs also on day 7, 14, and 30. The results show that Taxol-treated animals developed mechanical sensitivity and corresponding IENF loss. Animals receiving minocycline plus Taxol showed no hyperalgesia or loss of IENFs. This study confirms, for the first time, that a loss of IENFs occurs as a neuropathy develops, and further shows a protection against both IENF loss and hyperalgesia with minocycline treatment.
Introduction
Paclitaxel (Taxol; Bristol-Myers Squibb, NY, USA) is a chemotherapeutic agent that exerts anti-tumor effects by causing hyperstabilization of microtubules [13] , and is commonly used as a primary treatment in breast, lung, and ovarian cancers. Unfortunately, there are multiple side effects with Taxol treatment, including alopecia, emesis, diarrhea, and fatigue. While disruptive, these side effects tend to subside following completion of therapy. Conversely, the side effect of peripheral neuropathy is much more disruptive and persistent. Almost all patients treated with Taxol will experience symptoms of neuropathy by the third treatment cycle, and up to half of all patients will discontinue therapy as a result [9, 11, 32] .
Currently, the cause of chemoneuropathy is not well understood. However, there are several contributing physiological changes that occur following exposure to Taxol. Administration of Taxol has been found to activate microglia and astrocytes and lead to macrophage infiltration in the spinal cord [28] . Several proinflammatory cytokines are increased, including tumor necrosis factor-a (TNF-a), interleukin-1 (IL-1) and IL-6, and interferon-a (IFN-a) and 47] . Increased activity and prolonged afterdischarges in dorsal horn neurons have been recorded [4] .
Taxol treatment also results in loss of nerve fibers that innervate the epidermis [37] . These intraepidermal nerve fibers (IENFs) are bare nerve endings that enter the epidermis as Ad and C fibers cross the dermal/epidermal junction and shed their myelin ensheathment that was present within the dermis. They are particularly important in transmitting noxious mechanical and thermal information [24] , and loss of IENFs is seen in a host of chronic painful neuropathic conditions, including diabetes [15, 36] , complex regional pain syndrome [27] , and postherpetic neuralgia [30] . While there is much speculation that IENF loss is related to functional impairments, there is a paucity of research investigating this hypothesis. Such studies have found that IENF loss is most pronounced in areas specific to pain [26, 30, 34] , and decreased IENF density correlates with alterations to warmth detection [36] and pinprick sensitivity [43] . Theories have been proposed to link decreased IENFs to the generation of chronic pain [26] ; however, no studies have looked in parallel at the development of pain and IENF changes.
The present study sought to determine whether loss of IENFs coincided with the development of peripheral neuropathy following Taxol 
